SG10201913076PA - Pharmaceutical compositions comprising dimethyl fumarate - Google Patents

Pharmaceutical compositions comprising dimethyl fumarate

Info

Publication number
SG10201913076PA
SG10201913076PA SG10201913076PA SG10201913076PA SG10201913076PA SG 10201913076P A SG10201913076P A SG 10201913076PA SG 10201913076P A SG10201913076P A SG 10201913076PA SG 10201913076P A SG10201913076P A SG 10201913076PA SG 10201913076P A SG10201913076P A SG 10201913076PA
Authority
SG
Singapore
Prior art keywords
pharmaceutical compositions
dimethyl fumarate
fumarate
dimethyl
pharmaceutical
Prior art date
Application number
SG10201913076PA
Inventor
Jimenez Maria Planells
Lopez Begoña Duarte
Coll Pere Guiro
Original Assignee
Almirall Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49917530&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG10201913076P(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Almirall Sa filed Critical Almirall Sa
Publication of SG10201913076PA publication Critical patent/SG10201913076PA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • A61K9/2833Organic macromolecular compounds
    • A61K9/284Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846Poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225Polycarboxylic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1617Organic compounds, e.g. phospholipids, fats
    • A61K9/1623Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • A61K9/2018Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • A61K9/282Organic compounds, e.g. fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06Antianaemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2009Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
SG10201913076PA 2013-12-12 2014-12-05 Pharmaceutical compositions comprising dimethyl fumarate SG10201913076PA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP13382504 2013-12-12

Publications (1)

Publication Number Publication Date
SG10201913076PA true SG10201913076PA (en) 2020-02-27

Family

ID=49917530

Family Applications (3)

Application Number Title Priority Date Filing Date
SG10201913076PA SG10201913076PA (en) 2013-12-12 2014-12-05 Pharmaceutical compositions comprising dimethyl fumarate
SG10201913080VA SG10201913080VA (en) 2013-12-12 2014-12-05 Pharmaceutical compositions comprising dimethyl fumarate
SG10201802815UA SG10201802815UA (en) 2013-12-12 2014-12-05 Pharmaceutical compositions comprising dimethyl fumarate

Family Applications After (2)

Application Number Title Priority Date Filing Date
SG10201913080VA SG10201913080VA (en) 2013-12-12 2014-12-05 Pharmaceutical compositions comprising dimethyl fumarate
SG10201802815UA SG10201802815UA (en) 2013-12-12 2014-12-05 Pharmaceutical compositions comprising dimethyl fumarate

Country Status (31)

Country Link
US (2) US20160310457A1 (en)
EP (2) EP3079666B1 (en)
JP (3) JP6581088B2 (en)
KR (2) KR102335289B1 (en)
CN (2) CN105813634A (en)
AR (1) AR098746A1 (en)
AU (2) AU2014363792B2 (en)
BR (1) BR112016012179B1 (en)
CA (2) CA2932054C (en)
CL (1) CL2016001415A1 (en)
CY (1) CY1124336T1 (en)
DK (1) DK3079666T3 (en)
EA (1) EA201600457A1 (en)
ES (1) ES2860551T3 (en)
HK (1) HK1224212A1 (en)
HR (1) HRP20210468T1 (en)
HU (1) HUE054408T2 (en)
IL (2) IL287109B (en)
LT (1) LT3079666T (en)
MX (2) MX2016007105A (en)
MY (1) MY179355A (en)
NZ (2) NZ759411A (en)
PH (2) PH12016501043A1 (en)
PL (1) PL3079666T3 (en)
PT (1) PT3079666T (en)
RS (1) RS61658B1 (en)
SG (3) SG10201913076PA (en)
SI (1) SI3079666T1 (en)
TW (2) TWI687218B (en)
UA (2) UA120428C2 (en)
WO (1) WO2015086467A1 (en)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9326947B1 (en) 2014-02-28 2016-05-03 Banner Life Sciences Llc Controlled release fumarate esters
US10098863B2 (en) 2014-02-28 2018-10-16 Banner Life Sciences Llc Fumarate esters
US9636318B2 (en) 2015-08-31 2017-05-02 Banner Life Sciences Llc Fumarate ester dosage forms
AU2015222880B2 (en) 2014-02-28 2016-11-24 Banner Life Sciences Llc Controlled release enteric soft capsules of fumarate esters
US10085961B2 (en) 2015-06-01 2018-10-02 Sun Pharmaceutical Industries Limited Pharmaceutical compositions of dimethyl fumarate
US10631564B2 (en) 2015-06-19 2020-04-28 University Of Southern California Enterically coated microparticle compositions and methods for modified nutrient delivery
US10744070B2 (en) 2015-06-19 2020-08-18 University Of Southern California Enteral fast access tract platform system
WO2017040272A1 (en) * 2015-08-31 2017-03-09 Banner Life Sciences Llc Fumarate ester dosage forms
PL3397247T3 (en) * 2015-12-31 2023-09-18 Zakłady Farmaceutyczne Polpharma Sa Process for preparation of an enteric coated granulate comprising dimethyl fumarate
EP3407873A1 (en) * 2016-01-28 2018-12-05 Zaklady Farmaceutyczne Polpharma SA Process for preparation of a granulate comprising dimethyl fumarate
AU2017216861A1 (en) * 2016-02-12 2018-10-04 Universität Zürich Dimethyl fumarate (DMF) for prevention or treatment of gout, acne, diabetes, vitiligo and/or pyoderma gangrenosum
WO2017145036A1 (en) * 2016-02-25 2017-08-31 Aurobindo Pharma Ltd Pharmaceutical compositions comprising dimethyl fumarate
JP7308763B2 (en) * 2017-06-23 2023-07-14 アルミラル・ソシエダッド・アノニマ Pharmaceutical composition containing dimethyl fumarate
JP7000148B2 (en) * 2017-12-27 2022-01-19 日本化薬株式会社 A pharmaceutical composition containing dasatinib as an active ingredient
WO2020053218A1 (en) 2018-09-13 2020-03-19 Almirall, S.A. Treatment of psoriasis
WO2020053219A1 (en) 2018-09-13 2020-03-19 Almirall, S.A. Treatment of psoriasis
EP3977986A4 (en) * 2019-05-31 2022-07-20 CURACLE Co., Ltd. Enteric tablet containing dimethyl fumarate
US20230055674A1 (en) * 2019-11-07 2023-02-23 Asahi Kasei Kabushiki Kaisha Cellulose composition and tablet
US11903918B2 (en) 2020-01-10 2024-02-20 Banner Life Sciences Llc Fumarate ester dosage forms with enhanced gastrointestinal tolerability
EP4313023A1 (en) * 2021-04-02 2024-02-07 Biogen MA Inc. Combination treatment methods of multiple sclerosis

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4959389A (en) 1987-10-19 1990-09-25 Speiser Peter P Pharmaceutical preparation for the treatment of psoriatic arthritis
DE19848260C2 (en) 1998-10-20 2002-01-17 Fumapharm Ag Muri Fumaric microtablets
DE19853487A1 (en) * 1998-11-19 2000-05-25 Fumapharm Ag Muri Use of dialkyl fumarate for treating transplant rejection and autoimmune disease
DE10101307A1 (en) * 2001-01-12 2002-08-01 Fumapharm Ag Muri Fumaric acid derivatives as NF-kappaB inhibitor
PL2801355T3 (en) * 2004-10-08 2015-10-30 Fwp Ip Aps Controlled release pharmaceutical compositions comprising a fumaric acid ester
CN101056624A (en) * 2004-10-08 2007-10-17 Adi技术制药股份公司 Controlled release pharmaceutical compositions comprising a fumaric acid ester
MX2007013467A (en) * 2005-04-28 2008-01-21 Wyeth Corp Micronized tanaproget and compostions containing same.
EP1951206A1 (en) * 2005-10-07 2008-08-06 Aditech Pharma AB Controlled release pharmaceutical compositions comprising a fumaric acid ester
CN101304732A (en) * 2005-10-07 2008-11-12 Adi技术制药股份公司 Controlled release pharmaceutical compositions comprising a fumaric acid ester
EP1940382A2 (en) * 2005-10-07 2008-07-09 Aditech Pharma AB Combination therapy with fumaric acid esters for the treatment of autoimmune and/or inflammatory disorders
WO2009118764A1 (en) * 2008-03-28 2009-10-01 Panacea Biotec Limited Pharmaceutical composition comprising diclofenac and paracetamol
US20120034274A1 (en) 2009-01-09 2012-02-09 Forward Pharma A/S Pharmaceutical composition comprising one or more fumaric acid esters
ES2411972T5 (en) 2009-01-09 2021-10-27 Fwp Ip Aps Pharmaceutical formulation comprising one or more fumaric acid esters in an erosion matrix
EP2424357A4 (en) 2009-04-29 2012-10-10 Biogen Idec Inc Treatment of neurodegeneration and neuroinflammation
RU2013154355A (en) * 2011-06-03 2015-07-20 Ф. Хоффманн-Ля Рош Аг METHOD FOR TREATING MESOTHELIOMA INHIBITOR PI3K
RU2014125430A (en) 2011-11-24 2015-12-27 Синтон Бв CONTROLLED RELEASE OF PARTICLES CONTAINING DIMETHYLFUMARATE
JP6189333B2 (en) 2012-02-07 2017-08-30 バイオジェン エムエー インコーポレーテッド Pharmaceutical composition containing dimethyl fumarate

Also Published As

Publication number Publication date
AU2019268075B2 (en) 2020-12-17
MX2020009745A (en) 2020-10-08
IL245685B (en) 2021-10-31
JP2016540003A (en) 2016-12-22
TWI704915B (en) 2020-09-21
BR112016012179A2 (en) 2017-08-08
KR20160089397A (en) 2016-07-27
BR112016012179B1 (en) 2023-04-18
HK1224212A1 (en) 2017-08-18
EA201600457A1 (en) 2016-11-30
MY179355A (en) 2020-11-05
MX2016007105A (en) 2016-08-11
DK3079666T3 (en) 2021-03-22
JP6945603B2 (en) 2021-10-06
TWI687218B (en) 2020-03-11
US20210330628A1 (en) 2021-10-28
UA120428C2 (en) 2019-12-10
US20160310457A1 (en) 2016-10-27
IL287109A (en) 2021-12-01
HRP20210468T1 (en) 2021-05-14
CA2932054A1 (en) 2015-06-18
CY1124336T1 (en) 2022-07-22
PT3079666T (en) 2021-02-18
AR098746A1 (en) 2016-06-08
CN105813634A (en) 2016-07-27
CN114159421B (en) 2023-08-25
KR102335289B1 (en) 2021-12-06
JP2019218385A (en) 2019-12-26
CA2932054C (en) 2022-09-20
JP2021130689A (en) 2021-09-09
AU2019268075A1 (en) 2019-12-12
TW202011953A (en) 2020-04-01
PH12016501043B1 (en) 2016-07-04
RS61658B1 (en) 2021-04-29
UA123880C2 (en) 2021-06-16
TW201605435A (en) 2016-02-16
LT3079666T (en) 2021-03-25
KR20210150587A (en) 2021-12-10
JP6581088B2 (en) 2019-09-25
AU2014363792A1 (en) 2016-06-09
NZ720287A (en) 2020-05-29
EP3656379A1 (en) 2020-05-27
HUE054408T2 (en) 2021-09-28
SI3079666T1 (en) 2021-04-30
PH12016501043A1 (en) 2016-07-04
PL3079666T3 (en) 2021-09-06
ES2860551T3 (en) 2021-10-05
EP3079666B1 (en) 2021-02-03
EP3079666A1 (en) 2016-10-19
PH12019502610A1 (en) 2021-02-22
IL287109B (en) 2022-08-01
CL2016001415A1 (en) 2017-01-20
CA3135273A1 (en) 2015-06-18
NZ759411A (en) 2020-06-26
CN114159421A (en) 2022-03-11
AU2014363792B2 (en) 2019-11-14
IL245685A0 (en) 2016-06-30
SG10201913080VA (en) 2020-03-30
SG10201802815UA (en) 2018-05-30
KR102353201B1 (en) 2022-01-18
WO2015086467A1 (en) 2015-06-18

Similar Documents

Publication Publication Date Title
IL287109A (en) Pharmaceutical compositions comprising dimethyl fumarate
IL290378A (en) Pharmaceutical compositions containing dimethyl fumarate
IL288961A (en) Pharmaceutical compositions
PL3030262T3 (en) Combined pharmaceutical composition
PL2943181T3 (en) Pharmaceutical compositions
PL3043778T3 (en) Pharmaceutical compositions containing refametinib
ZA201408333B (en) Pharmaceutical compositions
SG11201601477VA (en) Pharmaceutical composition
SG11201509194SA (en) Radiomitigating pharmaceutical formulations
HRP20171888T1 (en) Pharmaceutical compositions
HK1220143A1 (en) Pharmaceutical composition
GB201304699D0 (en) Pharmaceutical compositions
GB201321497D0 (en) Pharmaceutical compositions
GB201312851D0 (en) Pharmaceutical compositions